Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of ZW251 in Participants With Advanced Solid Tumors
Sponsor: Zymeworks BC Inc.
Summary
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC).
Official title: A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-10-21
Completion Date
2028-05
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
ZW251
Administered intravenously
Locations (20)
UCSF Comprehensive Cancer Center
San Francisco, California, United States
Norton Cancer Institute
Louisville, Kentucky, United States
START Midwest
Grand Rapids, Michigan, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
MD Anderson Cancer Center
Houston, Texas, United States
START San Antonio
San Antonio, Texas, United States
START - Dublin Mater Misericordiae University Hospital (MMUH)
Dublin, Ireland
National Cancer Center East
Kashiwa, Japan
Kyoto University Hospital
Kyoto, Japan
Kansai Medical University Hospital
Osaka, Japan
National Cancer Center Hospital
Tokyo, Japan
START Lisboa a - Unidade de Ensaios ClÃnicos - Hospital de Santa Maria
Lisbon, Portugal
Hospital Universitario Vall d'Hebron
Barcelona, Spain
START Barcelona
Barcelona, Spain
START - Rioja Hospital Universitario San Pedro
Logroño, Spain
START Madrid Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
START Madrid Hospital Universitario HM Sanchinarro - CIOCC
Madrid, Spain
NEXT Oncology Madrid
Madrid, Spain
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan